Andy Studna, Senior Editor

In this video interview, Sujay Jadhav, CEO of Verana Health, highlights how the industry can use RWD to compare outcomes from treatment and non-treatment arms.

This framework marks the agency’s first official recommendation on the use of AI in drug development.

In this video interview, Sujay Jadhav, CEO of Verana Health, discusses how the use of unstructured data can help improve clinical research in 2025.

Intrathecal onasemnogene abeparvovec (OAV101 IT) demonstrated an increase from baseline in Hammersmith Functional Motor Scale – Expanded total score in children and young adults with SMA.

This year’s submissions highlight initiatives around accelerating enrollment, personalizing recruitment, increasing diversity, and more.

In this video interview, Rachael Fones, director, government & public affairs, IQVIA, discusses some of the key ways that different trial sponsors may need support in meeting diversity expectations.

Applied Clinical Trials sat down on-site with many KOLs at some of industry's largest gatherings in 2024 including SCOPE, DIA, and DPHARM.

In this video interview, Rachael Fones, director, government & public affairs, IQVIA, highlights the use of real-world data in setting population goals.

In this video interview, Rachael Fones, director, government & public affairs, IQVIA, discusses the importance of goal setting in the context of FDA’s latest Diversity Action Plan guidance.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), looks forward and shares her thoughts on future trends with clinical technology.

In patients with type 2 diabetic nephropathy, bremelanotide demonstrated efficacy in reducing urine protein to creatinine ratio and improving or stabilizing estimated glomerular filtration rate.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), highlights how DTRA is working with sites and sponsors to gauge the feasibility of site-validated technology use.

Duvakitug, a monoclonal antibody, demonstrated clinical remission and endoscopic response in the study, meeting its primary endpoints.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), discusses several initiatives DTRA is working on to keep sites in-the-know on DCT elements included in study protocols.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), highlights challenges with technology adoption including how sites may be asked to work with a variety of different providers.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), touches on the adoption of DCT elements and how it can affect study team members.

In the fifth and final part of this roundtable discussion, participants discuss the practice of designing technology with patients in mind and share their concluding thoughts on improving diversity in clinical trials.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), shares her most important takeaways from the event including how industry is becoming more and more ready to adopt decentralized elements.

In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), discusses how some stakeholders view DCTs only as fully remote trials.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, talks secure data transfer and risk mitigation.

Interim results from the lead-in cohort showed some patients who received LP-300 alongside chemotherapy experienced an average tumor size reduction of 51%.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, touches on the challenges with hand-written data collection and how they can be addressed with AI.

Palmese, executive director, site relationships and DCT solutions, discusses the practice of incorporating decentralized elements in a study rather than planning a decentralized trial from the start.

Industry experts discuss the use of decentralized technologies and the potential of artificial intelligence in reaching underrepresented patient populations.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, discusses how AI can be used to streamline sample collection and tracking.

Our November issue focused on patient centricity with additional coverage around data management.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, highlights the idea of consolidating clinical technology and how it may become more popular in the future.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, discusses the concept of data exhaust and how managing it can be simplified with artificial intelligence.

The PANOVA-3 study met its primary endpoint, demonstrating an improvement in overall survival for patients treated with Tumor Treating Fields.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, talks AI and how it can automate repetitive processes.